Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

[1]  G. Rustin,et al.  Effect of temozolomide on central nervous system relapse in patients with advanced melanoma , 2002, Melanoma research.

[2]  S. Steinberg,et al.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Kersten,et al.  Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Morton,et al.  Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Begg,et al.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Steinberg,et al.  Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Richards,et al.  Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Buzaid,et al.  Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Buckner,et al.  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Legha Ss.  Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. , 1997 .

[14]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Rustin,et al.  Brampton, M, Stevens MFG. Cancer Research Campaign phase-II trial of temozolomide in malignant melanoma , 1995 .

[16]  C. Borel,et al.  Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Borden,et al.  Prognostic factors in metastatic melanoma , 1993, Cancer.

[18]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[19]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[20]  L. Lanier,et al.  Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo , 1990, The Journal of experimental medicine.

[21]  M. Caligiuri,et al.  Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.

[22]  S. Lakhani,et al.  Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. , 1990, British Journal of Cancer.

[23]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[24]  R. Benjamin,et al.  A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases , 1985, American journal of clinical oncology.

[25]  V. Vaitkevicius,et al.  Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival , 1978, Cancer.